|
| 36824750 | Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. | Res Sq | 2023 |
| 35613015 | Maternal and prenatal factors and age at thelarche in the LEGACY Girls Study cohort: implications for breast cancer risk. | Int J Epidemiol | 2023 |
| 37596165 | Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. | Cancer Epidemiol | 2023 |
| 37789226 | Polymorphisms in genes of melatonin biosynthesis and signaling support the light-at-night hypothesis for breast cancer. | Eur J Epidemiol | 2023 |
| 36959380 | Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma. | Br J Cancer | 2023 |
| 36824750 | Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. | Res Sq | 2023 |
| 36707629 | FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women. | Eur J Hum Genet | 2023 |
| 37451831 | Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. | J Med Genet | 2023 |
| 37444426 | Spectrum and Frequency of Germline <i>FANCM</i> Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases. | Cancers (Basel) | 2023 |
| 36689693 | Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. | J Clin Oncol | 2023 |
| 36857773 | Diet Quality and All-Cause Mortality in Women with Breast Cancer from the Breast Cancer Family Registry. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 37503126 | Understanding the genetic complexity of puberty timing across the allele frequency spectrum. | medRxiv | 2023 |
| 37596165 | Genetically inferred birthweight, height, and puberty timing and risk of osteosarcoma. | Cancer Epidemiol | 2023 |
| 37789226 | Polymorphisms in genes of melatonin biosynthesis and signaling support the light-at-night hypothesis for breast cancer. | Eur J Epidemiol | 2023 |
| 37503126 | Understanding the genetic complexity of puberty timing across the allele frequency spectrum. | medRxiv | 2023 |
| 35613015 | Maternal and prenatal factors and age at thelarche in the LEGACY Girls Study cohort: implications for breast cancer risk. | Int J Epidemiol | 2023 |
| 37451831 | Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. | J Med Genet | 2023 |
| 37444426 | Spectrum and Frequency of Germline <i>FANCM</i> Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases. | Cancers (Basel) | 2023 |
| 36959380 | Functional genomics of human clear cell sarcoma: genomic, transcriptomic and chemical biology landscape for clear cell sarcoma. | Br J Cancer | 2023 |
| 36857773 | Diet Quality and All-Cause Mortality in Women with Breast Cancer from the Breast Cancer Family Registry. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 36689693 | Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival. | J Clin Oncol | 2023 |
| 36707629 | FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women. | Eur J Hum Genet | 2023 |
| 34320204 | Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. | J Natl Cancer Inst | 2022 |
| 35585550 | Breast cancer risks associated with missense variants in breast cancer susceptibility genes. | Genome Med | 2022 |
| 36205748 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. | Genet Med | 2022 |
| 35933885 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model. | Eur J Cancer | 2022 |
| 35418701 | Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. | Sci Rep | 2022 |
| 36328784 | Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. | Br J Sports Med | 2022 |
| 35777474 | Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk. | J Pediatr | 2022 |
| 34320204 | Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. | J Natl Cancer Inst | 2022 |
| 35042965 | Rare germline copy number variants (CNVs) and breast cancer risk. | Commun Biol | 2022 |
| 34906479 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. | Genet Med | 2022 |
| 34965921 | Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). | Cancer Prev Res (Phila) | 2022 |
| 35158816 | Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma. | Cancers (Basel) | 2022 |
| 35077220 | Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. | J Clin Oncol | 2022 |
| 35157067 | Body mass index rebound and pubertal timing in girls with and without a family history of breast cancer: the LEGACY girls study. | Int J Epidemiol | 2022 |
| 35084436 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. | JAMA Oncol | 2022 |
| 35585550 | Breast cancer risks associated with missense variants in breast cancer susceptibility genes. | Genome Med | 2022 |
| 35418701 | Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. | Sci Rep | 2022 |
| 35777474 | Mother and Daughter Perspectives on Genetic Counseling and Testing of Adolescents for Hereditary Breast Cancer Risk. | J Pediatr | 2022 |
| 36205748 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. | Genet Med | 2022 |
| 35933885 | Incorporating progesterone receptor expression into the PREDICT breast prognostic model. | Eur J Cancer | 2022 |
| 36328784 | Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. | Br J Sports Med | 2022 |
| 35158816 | Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma. | Cancers (Basel) | 2022 |
| 35157067 | Body mass index rebound and pubertal timing in girls with and without a family history of breast cancer: the LEGACY girls study. | Int J Epidemiol | 2022 |
| 35042965 | Rare germline copy number variants (CNVs) and breast cancer risk. | Commun Biol | 2022 |
| 34906479 | Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. | Genet Med | 2022 |
| 35084436 | Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. | JAMA Oncol | 2022 |
| 34965921 | Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). | Cancer Prev Res (Phila) | 2022 |
| 35077220 | Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants. | J Clin Oncol | 2022 |